Highly complex robotic knee replacement surgery performed at Sohana Multi-Speciality Hospital in Mohali in Punjab: Our Bureau ...
Enlitic & GE HealthCare collaborate to redefine imaging data migration and cloud solutions for enterprise imaging: Fort Collins, Colorado Wednesday, February 19, 2025, 17:00 Hrs [ ...
Maharashtra FDA to address regulatory gaps for strengthening compliance and quality: Shardul Nautiyal, Mumbai Wednesday, ...
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...
ISB MIHM study reveals mixed attitudes on AI for tuberculosis diagnosis in India's informal healthcare sector: Our Bureau, Bengaluru Wednesday, February 19, 2025, 15:45 Hrs [IST] ...
KL Krems study shows high-volume liposuction significantly increases the likelihood of secondary complications in anaemic lipoedema patients: Krems, Austria Wednesday, February 19 ...
Leucine-Rich Bio expands global reach partnering with Precision Diagnostics to market BugSpeaks to Brazil: Our Bureau, Bengaluru Wednesday, February 19, 2025, 16:15 Hrs [IST] Leuc ...
US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001: Seongnam, South Korea Wednesday, February 19, 2025, 16:00 Hrs [IST] Rznomics, ...
Lupin receives “A-” Leadership Rating from CDP in two categories – climate change and water security
Global pharma major Lupin Limited (Lupin) announced that it has received an “A-” leadership rating from CDP for its outstanding performance in climate change and water security. This rating reflects ...
Jujhar Group with Apollo Hospitals to set up advanced super-speciality unit in Mohali: Our Bureau, Bengaluru Wednesday, February 19, 2025, 14:50 Hrs [IST] Punjab-based Jujhar Grou ...
Queensland to expand global healthcare frontiers at BioAsia 2025: Our Bureau, Bengaluru Wednesday, February 19, 2025, 14:15 Hrs [IST] Trade and Investment Queensland (TIQ), the de ...
AlgoTherapeutix announces results of its phase 2 “ACT” trial of ATX01 in chemotherapy-induced peripheral neuropathy: Paris, France Wednesday, February 19, 2025, 13:00 Hrs [IST ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results